|Daily Range||$23.90 - $24.31|
|52-Week Range||$21.51 - $27.52|
|Dividend (Yield)||$0.00 (2.6%)|
|Average Daily Volume||29,022|
|Current FY EPS||$0.37|
It was expected to be Orexigen's greatest selling point, but this miscue turned into a nightmare for the company's weight-control management drug Contrave.
The revenue potential of this company's lead product candidate looks astounding.
Our contributors think its time to head for the exits on these three biotechs.
Tension between Orexigen and its marketing partner Takeda Pharmaceuticals continues to build after reports of a recall on obesity medication Contrave surface.
Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.
Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.
The pharmaceutical market is headed for $1.3 trillion by 2016. Here's how globalization is radically changing the game for Big Pharma and Big Biotech players.
After reporting first-quarter financials Friday, ImmunoGen Inc.'s shares fell despite bullish analyst reports.
Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.
Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.